Core Insights - Curative Biotechnology, Inc. has received a Notice of Allowance for a Canadian patent related to a novel pharmacological target for treating retinal degeneration, which is a significant advancement for the company [1][3] - The company holds an exclusive worldwide license for this technology from the National Eye Institute, indicating a strong partnership with a reputable institution [1][6] - Curative plans to expand its metformin-based eye drop program into veterinary applications, specifically targeting canine retinal degenerative diseases, which may enhance the overall value of its platform [4][5] Intellectual Property - The Canadian patent includes 22 allowed claims focused on topical ocular delivery methods relevant to metformin-based formulations, aligning with the company's intended administration route [3] - The patent is expected to be formally issued in the coming months, further solidifying the company's intellectual property portfolio [3] Development Plans - Curative's primary focus is on developing a metformin-based reformulation for treating intermediate and late-stage Age-Related Macular Degeneration (AMD), with a first-in-human clinical trial planned for 2026 [6] - The company is also exploring parallel development pathways in veterinary ophthalmology, addressing unmet needs in canine retinal diseases [4][5]
Curative Biotechnology Announces Canadian Patent Allowance
Globenewswire·2026-01-23 13:45